Genprex (NASDAQ:GNPX) Stock Price Down 1.1% – Here’s What Happened
by Jessica Moore · The Cerbat GemGenprex (NASDAQ:GNPX – Get Free Report)’s stock price dropped 1.1% during trading on Monday. The stock traded as low as $2.57 and last traded at $2.69. 275,523 shares traded hands during trading, an increase of 1% from the average daily volume of 272,023 shares. The stock had previously closed at $2.72.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on Genprex
Genprex Trading Down 7.2%
The company has a market cap of $1.91 million, a price-to-earnings ratio of -0.02 and a beta of -0.99. The stock’s fifty day simple moving average is $3.54 and its 200 day simple moving average is $12.56.
Genprex (NASDAQ:GNPX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($9.40) earnings per share for the quarter.
Hedge Funds Weigh In On Genprex
An institutional investor recently bought a new stake in Genprex stock. Mayflower Financial Advisors LLC acquired a new stake in Genprex (NASDAQ:GNPX – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $36,000. Mayflower Financial Advisors LLC owned about 0.22% of Genprex as of its most recent filing with the Securities and Exchange Commission (SEC). 14.05% of the stock is owned by institutional investors.
Genprex Company Profile
Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s lead product candidate is ofranergene obadenovec, also known as REQORSA Therapeutics, an investigational nonviral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells.
Genprex has primarily studied REQORSA in combination with other treatments for non-small cell lung cancer, including immune checkpoint inhibitors and targeted therapies.